Response Genetics, a company focused on the development and sale of molecular diagnostic tests for cancer, has announced that Thomas Stankovich has resigned from his position as chief financial officer (CFO) to pursue other interests. Stankovich will complete the filing of the company’s 2009 Annual Report on Form 10-K and has agreed to be available beyond his resignation date to assist in the transition of his role.
The company has commenced a search for a new CFO. In the interim, Eric Alcorn, vice president of finance and administration, will assume Stankovich’s responsibilities. Alcorn has been with the company since its inception.
Stankovich joined Response Genetics in November 2006. He has been responsible for management of the company’s finance functions, strategic planning and administrative services.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.